Previous 10 | Next 10 |
2023-05-19 10:04:48 ET Gainers: Lucy Scientific Discovery ( LSDI ) +51% . Bioventus ( BVS ) +44% . Mallinckrodt ( MNK ) +28% . 180 Life Sciences ( ATNF ) +28% . Stereotaxis ( STXS ) +25% . Losers: Enveric Biosciences ( ENVB ...
2023-05-16 10:07:34 ET Gainers: Phio Pharmaceuticals ( PHIO ) +30% . Coya Therapeutics ( COYA ) +23% . Nanobiotix ( NBTX ) +12% . Savara ( SVRA ) +12% . Bellerophon Therapeutics ( BLPH ) +11% . Losers: Eloxx Pharmaceutical...
2023-05-15 17:31:26 ET Bellerophon Therapeutics press release ( NASDAQ: BLPH ): Q1 GAAP EPS of $0.27. Revenue of $5.64M. For further details see: Bellerophon Therapeutics GAAP EPS of $0.27, revenue of $5.64M
Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a c...
WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient ...
2023-04-04 12:51:54 ET Gainers: Cardlytics ( CDLX ) +62% . Assure Holdings ( IONM ) +56% . The NFT Gaming Company ( NFTG ) +42% . Bullfrog AI Holdings ( BFRG ) +32% . Bellerophon Therapeutics ( BLPH ) +27% . Austin Gold ( A...
2023-03-31 08:42:17 ET Bellerophon Therapeutics press release ( NASDAQ: BLPH ): FY GAAP EPS of -$2.08 misses by $0.06 . As of December 31, 2022, the Company had unrestricted cash and cash equivalents of $6.9 million, compared to unrestricted cash and cash equivalents o...
Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023 Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater China Strengthened Balance Sheet Through $5 Million Registered Direct Offering with ...
2023-03-20 13:07:07 ET Gainers: Loyalty Ventures ( LYLT ) +97% . Ambipar Emergency ( AMBI ) +73% . Lifecore Biomedical ( LFCR ) +60% . InMed Pharmaceuticals ( INM ) +43% . New York Community Bancorp ( NYCB ) +32% . Harbor Cus...
2023-03-20 10:29:09 ET Gainers: Lifecore Biomedical ( LFCR ) +41% . Connect Biopharma ( CNTB ) +27% . InMed Pharmaceuticals ( INM ) +21% . ReShape Lifesciences ( RSLS ) +21% . Bellerophon Therapeutics ( BLPH ) +15% . Losers...
News, Short Squeeze, Breakout and More Instantly...
Bellerophon Therapeutics Inc. Company Name:
BLPH Stock Symbol:
NASDAQ Market:
Bellerophon Therapeutics Inc. Website:
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...